- Home
- EBS vs ALLO Comparison
EBS vs ALLO Comparison
Compare EBS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- ALLO
- Stock Information
- Founded
- EBS 1998
- ALLO 2017
- Country
- EBS United States
- ALLO United States
- Employees
- EBS N/A
- ALLO N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBS Health Care
- ALLO Health Care
- Exchange
- EBS Nasdaq
- ALLO Nasdaq
- Market Cap
- EBS 359.3M
- ALLO 277.8M
- IPO Year
- EBS 2006
- ALLO 2018
- Fundamental
- Price
- EBS $6.92
- ALLO $1.25
- Analyst Decision
- EBS Strong Buy
- ALLO Strong Buy
- Analyst Count
- EBS 3
- ALLO 9
- Target Price
- EBS $14.33
- ALLO $8.44
- AVG Volume (30 Days)
- EBS 1.5M
- ALLO 3.2M
- Earning Date
- EBS 08-06-2025
- ALLO 08-06-2025
- Dividend Yield
- EBS N/A
- ALLO N/A
- EPS Growth
- EBS N/A
- ALLO N/A
- EPS
- EBS N/A
- ALLO N/A
- Revenue
- EBS $965,400,000.00
- ALLO N/A
- Revenue This Year
- EBS N/A
- ALLO N/A
- Revenue Next Year
- EBS $16.15
- ALLO $199.63
- P/E Ratio
- EBS N/A
- ALLO N/A
- Revenue Growth
- EBS N/A
- ALLO N/A
- 52 Week Low
- EBS $4.02
- ALLO $0.86
- 52 Week High
- EBS $15.10
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- EBS 53.49
- ALLO 54.67
- Support Level
- EBS $6.59
- ALLO $1.13
- Resistance Level
- EBS $7.65
- ALLO $1.33
- Average True Range (ATR)
- EBS 0.40
- ALLO 0.08
- MACD
- EBS 0.02
- ALLO 0.01
- Stochastic Oscillator
- EBS 49.31
- ALLO 81.82
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.